AdvanCell raised $315 million in a Series D to fund a lead prostate cancer radiopharmaceutical program and to support U.S. manufacturing capacity. The financing is aimed at advancing a Pluvicto challenger through development and scaling processes for radioactive therapy supply. The round signals continued appetite for radiopharma platforms that can compete on both clinical outcomes and manufacturing readiness—an increasingly critical differentiator as radioligand therapies expand beyond early-line use. By tying the capital to both a development program and manufacturing “shore-up,” AdvanCell is explicitly addressing the operational constraints that have historically limited throughput for radiopharmaceutical commercialization. For investors and peers, the size of the round reflects how the radiopharma opportunity remains high, even as competition intensifies around next-generation PSMA-targeting and dose-optimization strategies.